Posted by Michael Wonder on 03 Mar 2020
Hereditary amyloidosis community hopes positive funding recommendations for new treatments lead to swift access for patients
2 March 2020 - Hereditary Amyloidosis Canada is joined by the Regroupement québécois des maladies orphelines in commending the CADTH) and INESSS for both recommending that Tegsedi (inotersen) and Onpattro (patisiran) be reimbursed by public drug plans for the treatment of polyneuropathy in adults with hereditary transthyretin-mediated amyloidosis.
"We're so pleased that the voices of hATTR amyloidosis patients, families and their caregivers are being heard regarding the dire need for publicly funded access to new treatment options like Tegsedi and Onpattro," said Anne Marie Carr, Founder and President of Hereditary Amyloidosis Canada.
"We urge all provincial and territorial governments to make these therapies accessible through their respective drug plans as quickly as possible to allow for the best possible outcomes for patients living with this life-limiting disease."
